{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:08:13Z","timestamp":1789380493442,"version":"build-2803163510"},"reference-count":58,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Early-stage non-small cell lung cancer (NSCLC) accounts for nearly 50% of cases. Surgery remains the cornerstone of curative treatment, but five-year survival is suboptimal, necessitating adjuvant, neoadjuvant, and perioperative strategies including chemotherapy, targeted therapy, and immunotherapy. Methods: We reviewed randomized trials and conference abstracts from the last decade up to August 2025 on adjuvant, neoadjuvant, and perioperative systemic therapies in resectable NSCLC, focusing on major pathological response, pathological complete response, event-free survival (EFS), and overall survival (OS), and also highlighting several ongoing trials in this setting. Results: The review generated a simplified treatment algorithm to assist clinicians in navigating the multiple therapeutic options for resectable NSCLC. Cisplatin-based adjuvant chemotherapy remains standard for stage II\u2013IIIA disease, while targeted therapy (osimertinib, alectinib) improves DFS in EGFR- and ALK-positive tumors. Adjuvant immunotherapy (atezolizumab, pembrolizumab) shows benefit primarily in PD-L1-positive patients, though regulatory approvals differ depending on PD-L1 expression thresholds. Neoadjuvant nivolumab plus chemotherapy significantly improved EFS and OS, particularly in stage IIIA (CheckMate 816). Perioperative regimens with nivolumab, durvalumab, or pembrolizumab show consistent EFS gains, most pronounced in stage III N2 patients. Emerging biomarkers such as residual viable tumor and circulating tumor DNA after surgery may further personalize therapy. Conclusions: Treatment of resectable NSCLC should be individualized based on stage, nodal status, PD-L1 expression, molecular alterations and pCR. Upfront surgery with adjuvant therapy is appropriate for lower-stage disease (IB\u2013IIA), while perioperative chemoimmunotherapy offers maximal benefit in stage II\u2013III, especially N2-positive patients. Biomarker-driven strategies will continue to refine patient selection to stop or continue postoperative treatment.<\/jats:p>","DOI":"10.3390\/cancers18182963","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:34:01Z","timestamp":1789378441000},"page":"2963","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multiple Options, One Objective: Clearer Decisions in Resectable Non-Small Cell Lung Cancer"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7189-6021","authenticated-orcid":false,"given":"Elio","family":"Nohra","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Saint Joseph University of Beirut, Beirut 1104 2020, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3090-127X","authenticated-orcid":false,"given":"Tala","family":"Najdi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Saint Joseph University of Beirut, Beirut 1104 2020, Lebanon"},{"name":"Department of Hematology-Oncology, Hotel-Dieu de France University Hospital, Beirut 1104 2020, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axelle Serena","family":"El Karak","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, European University Cyprus, Nicosia 1516, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghadi","family":"Dagher","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Saint Joseph University of Beirut, Beirut 1104 2020, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9266-591X","authenticated-orcid":false,"given":"Fadi","family":"El Karak","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Saint Joseph University of Beirut, Beirut 1104 2020, Lebanon"},{"name":"Department of Hematology-Oncology, Hotel-Dieu de France University Hospital, Beirut 1104 2020, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"ref_1","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Garinet, S., Wang, P., Mansuet-Lupo, A., Fournel, L., Wislez, M., and Blons, H. (2022). Updated Prognostic Factors in Localized NSCLC. Cancers, 14.","DOI":"10.3390\/cancers14061400"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Tang, W.-F., Ye, H.-Y., Tang, X., Su, J.-W., Xu, K.-M., Zhong, W.-Z., and Liang, Y. (2023). Adjuvant immunotherapy in early-stage resectable non\u2013small cell lung cancer: A new milestone. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1063183"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"(1995). Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ, 311, 899\u2013909.","DOI":"10.1136\/bmj.311.7010.899"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s43046-025-00264-4","article-title":"Unlocking the therapeutic potential of antibody\u2013drug conjugates in targeting molecular biomarkers in non-small cell lung cancer","volume":"37","author":"Soni","year":"2025","journal-title":"J. Egypt. Natl. Cancer Inst."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"11795549241260534","DOI":"10.1177\/11795549241260534","article-title":"Exploring the Potential of Antibody-Drug Conjugates in Targeting Non-small Cell Lung Cancer Biomarkers","volume":"18","author":"Khadela","year":"2024","journal-title":"Clin. Med. Insights Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa031644","article-title":"International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer","volume":"350","author":"Arriagada","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1470-2045(06)70804-X","article-title":"Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB\u2013IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomised controlled trial","volume":"7","author":"Douillard","year":"2006","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): A randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"ref_10","unstructured":"(2025, September 22). Non-Small Cell Lung Cancer\u2014Guidelines Detail. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1450."},{"key":"ref_11","unstructured":"Rosa, K. (2025, September 22). Adjuvant Atezolizumab Approved in Europe for High-Risk NSCLC with PD-L1 of \u226550%|OncLive. Available online: https:\/\/www.onclive.com\/view\/adjuvant-atezolizumab-approved-in-europe-for-high-risk-nsclc-with-pd-l1-of-50-."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB\u2013IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): An interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"Marreaud","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jtho.2021.10.014","article-title":"Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC","volume":"17","author":"Wu","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(17)30729-5","article-title":"Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT\/CTONG1104): A randomised, open-label, phase 3 study","volume":"19","author":"Zhong","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in Resected ALK-Positive Non\u2013Small-Cell Lung Cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S1238","DOI":"10.1016\/j.annonc.2024.08.2289","article-title":"LBA48 CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC)","volume":"35","author":"Goss","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_17","unstructured":"National Cancer Institute (NCI) (2025, September 30). Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers. ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02595944."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2217\/imt-2021-0019","article-title":"Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO)","volume":"13","author":"Sands","year":"2021","journal-title":"Immunotherapy"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1038\/s41591-022-01962-5","article-title":"Neoadjuvant atezolizumab for resectable non-small cell lung cancer: An open-label, single-arm phase II trial","volume":"28","author":"Chaft","year":"2022","journal-title":"Nat. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 Blockade in Resectable Lung Cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41591-020-01224-2","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: The phase 2 randomized NEOSTAR trial","volume":"27","author":"Cascone","year":"2021","journal-title":"Nat. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"8532","DOI":"10.1200\/JCO.2018.36.15_suppl.8532","article-title":"Neoadjuvant atezolizumab + chemotherapy in resectable non-small cell lung cancer (NSCLC)","volume":"36","author":"Shu","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"LBA8010","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8010","article-title":"Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816","volume":"42","author":"Spicer","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa2215530","article-title":"Perioperative Nivolumab and Chemotherapy in Stage III Non\u2013Small-Cell Lung Cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S1470-2045(24)00498-4","article-title":"Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial","volume":"25","author":"Provencio","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative Nivolumab in Resectable Lung Cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S1297","DOI":"10.1016\/j.annonc.2023.10.052","article-title":"LBA56 Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)","volume":"34","author":"Spicer","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.21.00276","article-title":"SAKK 16\/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients with Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial","volume":"39","author":"Rothschild","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative Durvalumab for Resectable Non\u2013Small-Cell Lung Cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_31","unstructured":"(2025, September 28). Toripalimab Plus Chemotherapy in Neoadjuvant\/Adjuvant Settings Improves EFS vs Chemotherapy Alone in Stage III NSCLC. Available online: https:\/\/dailynews.ascopubs.org\/do\/10.1200\/ADN.23.201345\/full\/."},{"key":"ref_32","unstructured":"AstraZeneca (2025, September 14). A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable, Early-Stage (II to IIIB) Non-Small Cell Lung Cancer (NeoCOAST-2). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05061550."},{"key":"ref_33","unstructured":"Novartis Pharmaceuticals (2025, September 14). Phase II Trial of Neoadjuvant and Adjuvant Capmatinib in Participants with Stages IB-IIIA, N2 and Selected IIIB (T3N2 or T4N2) NSCLC with MET Exon 14 Skipping Mutation or High MET Amplification (Geometry-N). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04926831."},{"key":"ref_34","unstructured":"Eli Lilly and Company (2025, September 14). LIBRETTO-432: A Placebo-Controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET Fusion-Positive NSCLC. ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04819100."},{"key":"ref_35","unstructured":"Genentech, Inc. (2025, September 14). NAUTIKA1: Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-Selected Patients with Resectable Stages IB-III Non-Small Cell Lung Cancer. ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04302025."},{"key":"ref_36","unstructured":"Li, M.S. (2025, September 14). Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer: An Open-Label, Multicenter, Single Arm Phase 2 Study. ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06055465."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jtcvs.2025.09.017","article-title":"TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non-small cell lung cancer","volume":"171","author":"Jones","year":"2026","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1038\/s41591-025-03746-z","article-title":"Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: The platform phase 2 NeoCOAST-2 trial","volume":"31","author":"Cascone","year":"2025","journal-title":"Nat. Med."},{"key":"ref_39","unstructured":"Memorial Sloan Kettering Cancer Center (2026, August 29). A Phase II Trial of Neoadjuvant Trastuzumab Deruxtecan for Patients with Stage II-III HER2-Amplified or HER2-Mutated Non-Small Cell Lung Cancer (HERCULES). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT07428044."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s12032-023-02005-w","article-title":"A review of recent advances in the novel therapeutic targets and immunotherapy for lung cancer","volume":"40","author":"Khadela","year":"2023","journal-title":"Med. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Khadela, A., Chavda, V.P., Postwala, H., Ephraim, R., Apostolopoulos, V., and Shah, Y. (2023). Configuring Therapeutic Aspects of Immune Checkpoints in Lung Cancer. Cancers, 15.","DOI":"10.3390\/cancers15020543"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e002248","DOI":"10.1136\/jitc-2020-002248","article-title":"Neoadjuvant immunotherapy for non-small cell lung cancer: Right drugs, right patient, right time?","volume":"9","author":"Ahern","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Kalvapudi, S., Vedire, Y., Yendamuri, S., and Barbi, J. (2023). Neoadjuvant therapy in non-small cell lung cancer: Basis, promise, and challenges. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1286104"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jss.2017.10.025","article-title":"Survival after radiation for stage I and II non-small cell lung cancer with positive margins","volume":"223","author":"Gulack","year":"2018","journal-title":"J. Surg. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.chest.2023.11.042","article-title":"Recurrence-Free Survival in Patients with Surgically Resected Non-Small Cell Lung Cancer: A Systematic Literature Review and Meta-Analysis","volume":"165","author":"Rajaram","year":"2024","journal-title":"CHEST"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"449","DOI":"10.5090\/kjtcs.2013.46.6.449","article-title":"Prognosis of Recurrence after Complete Resection in Early-Stage Non-Small Cell Lung Cancer","volume":"46","author":"Choi","year":"2013","journal-title":"Korean J. Thorac. Cardiovasc. Surg."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Son, J.W., Lee, J., Jeon, J.H., Cho, S., Jung, W., Shih, B.C.-H., Kim, K., and Jheon, S. (2024). Validation of IASLC 9th edition TNM classification for lung cancer: Focus on N descriptor. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-13139-z"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group","volume":"26","author":"Pignon","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jtho.2018.03.035","article-title":"A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Na\u00efve Patients with Advanced NSCLC","volume":"13","author":"Lisberg","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"9753","DOI":"10.1038\/s41598-022-13102-7","article-title":"PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment na\u00efve advanced EGFR-mutant non-small cell lung cancer patients","volume":"12","author":"Hsu","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Kumar, A., Tohmasi, S., Eaton, D.B., Seyoum, N., Brandt, W.S., Thomas, T.S., Schoen, M.W., Rossetti, N.E., Chang, S.-H., and Yan, Y. (2025). Real-World Adoption of Adjuvant Therapies for Resected Stage IB\u2013III Non-Small-Cell Lung Cancer. Cancers, 17.","DOI":"10.3390\/cancers17182961"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00262-025-04130-z","article-title":"Is adjuvant immunotherapy necessary after neoadjuvant chemoimmunotherapy in patients with resectable stage III NSCLC? A two-center real-world study","volume":"74","author":"Guan","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Mao, Y., Chen, F., Ye, Z., Li, Z., Fan, B., Zou, Y., Li, W., and Lan, F. (2024). Neoadjuvant immune checkpoint inhibitor reduced recurrence in operable NSCLC patients with pathological complete response: A retrospective analysis. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-13142-4"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jtcvs.2025.04.028","article-title":"Lung cancer recurrence after neoadjuvant immunotherapy","volume":"170","author":"Li","year":"2025","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Ohara, S., Suda, K., and Tsutani, Y. (2025). Utility and Future Perspectives of Circulating Tumor DNA Analysis in Non-Small Cell Lung Cancer Patients in the Era of Perioperative Chemo-Immunotherapy. Cells, 14.","DOI":"10.20944\/preprints202507.2581.v1"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e20250022","DOI":"10.36416\/1806-3756\/e20250022","article-title":"Out with the old\u2014Advancements and shortcomings of the updated 9th edition of the Tumor, Node, Metastasis (TNM) classification system for lung cancer","volume":"51","author":"Ferreira","year":"2025","journal-title":"J. Bras. Pneumol."},{"key":"ref_58","unstructured":"Helwick, C. (2026, April 05). Patient-Level Data Support Perioperative Use of Nivolumab in Resectable NSCLC. Available online: https:\/\/ascopost.com\/issues\/november-25-2024-supplement-conference-highlights-2024-wclc\/patient-level-data-support-perioperative-use-of-nivolumab-in-resectable-nsclc\/."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/2963\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:49:43Z","timestamp":1789379383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/2963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":58,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cancers18182963"],"URL":"https:\/\/doi.org\/10.3390\/cancers18182963","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]}}}